Adi Mor
Algemeen Directeur bij CHEMOMAB THERAPEUTICS LTD.
Vermogen: 18 723 $ op 30-04-2024
Momenteel actieve connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Stephen P. Squinto | M | 67 |
Chemomab Ltd.
 Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 1 jaar |
| Nissim Darvish | M | 59 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 3 jaar |
| Neil Cohen | M | 60 | 4 jaar | |
| Sigal Fattal | F | 53 | 4 jaar | |
| Claude Nicaise | M | 71 | 3 jaar | |
| Alan Moses | M | 76 | 3 jaar | |
| Barbara Lindheim | F | - | - | |
| Nissim Mashiach | M | 63 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Sharon Hashmueli | M | - | 8 jaar | |
| Jill Quigley | F | 49 | 2 jaar | |
| Jason Camm | M | 35 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Jack Lawler | M | - | 2 jaar | |
| Ilan Vaknin | M | - | 2 jaar | |
| Matthew B. Frankel | M | 56 | 2 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
| Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
|---|---|---|---|---|
| Dale Pfost | M | - | 2 jaar | |
| Donald Marvin | M | - | 2 jaar | |
| Jacob George | M | 59 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | - |
| Joel Maryles | M | 64 | 1 jaar | |
| Sharon Elkobi | F | - | 3 jaar | |
| Bryan Jennings | M | - |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 1 jaar |
| Efrat Makov | F | 56 | 2 jaar | |
| David Ben-Ami | M | 63 |
Chemomab Ltd.
Chemomab Ltd. BiotechnologyHealth Technology ChemomAb Ltd. develops novel chemokine blocking therapies for inflammatory and fibrotic disorders. It specializes in the development of proprietary monoclonal antibodies, directed towards novel targets, for the treatment of immune-mediated and fibrotic disorders including orphan indications. The company was founded by Adi Mor and Jacob George in 2011 and is headquartered Tel Aviv, Israel. | 4 jaar |
| Mitchell Jones | M | 46 | - | |
| Arnon Aharon | M | 55 | 5 jaar | |
| David Weiner | M | 59 | 1 jaar | |
| Michal Segal-Salto | M | 51 | 7 jaar |
Statistieken
| Land | Connecties | % van het totaal |
|---|---|---|
| Israël | 26 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
